Active and Latent Tuberculosis in Children Treated with Anti-TNF-α: A Retrospective Multicenter Study

Abstract

Objective This study aimed to investigate the frequency of latent and active tuberculosis (TB) in pediatric patients receiving anti-tumor necrosis factor (TNF)-α therapy.

Methods Patients younger than 18 years with various inflammatory diseases and treated with anti-TNF-α agents in the past five years were included in the study. The patients' ages, follow-ups, medications received, clinical and laboratory findings, and treatments applied were recorded retrospectively.

Results Of the 160 patients included in the study, 78 (48.8%) were girls. The mean age was 139.54 ± 48.74 (30–226) months. Sixty (37.5%) patients had inflammatory eye disease, 55 (34.4%) had rheumatologic and autoimmune disease, and 45 (28.1%) had inflammatory bowel disease. As anti-TNF-α treatment, 67 (41.9%) patients received adalimumab, 50 (31.2%) received infliximab, and 43 (26.9%) received etanercept. As a result of TB screening performed prior to the treatment, 44 (25.4%) patients were started on isoniazid treatment with the diagnosis of latent TB. During follow-up, latent TB infection was detected in 16 (9.2%) patients and isoniazid treatment was started. The time to develop latent TB under anti-TNF-α treatment ranged from 3 to 28 months. During the treatment, active TB infection developed in two (1.2%) patients and anti-TB treatment was initiated.

Conclusion It is of vital importance to evaluate patients receiving, or planned to receive, anti-TNF-α treatment, for TB infection and to initiate appropriate treatments if latent or active TB infection is identified.

Keywords

tumor necrosis factor - tuberculosis - children

Publikationsverlauf

Eingereicht: 17. Februar 2021

Angenommen: 04. Januar 2022

Artikel online veröffentlicht:
28. Februar 2022

• References

• 1 Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol 2016; 117 (02) 115-120
• 2 Davies HD. Committee on Infectious Diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics 2016; 138 (02) e20161209
• 3 Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents. Pediatr Rheumatol Online J 2014; 12 (01) 45
• 4 Gardam MA, Keystone EC, Menzies R. et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3 (03) 148-155
• 5 Hsia EC, Schluger N, Cush JJ. et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64 (07) 2068-2077
• 6 Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr 2016;4(06):
• 7 Global Tuberculosis Report 2019. Accessed on September 9, 2020 at: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf
• 8 Tüberküloz Tanı ve Tedavi Rehberi. 2019 . Accessed on September 9, 2020 at: https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz_db/haberler/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_/Tuberkuloz_Tani_ve_Tedavi_Rehberi_08.07.2019_Yuksek_KB.pdf
• 9 Robert Horsburgh Jr C. Epidemiology of tuberculosis. In: Baron EL. ed. UpToDate. Accessed September 9, 2020 at: http://www.uptodate.com/home
• 10 Anti-TNF Kullanan Hastalarda Tüberküloz Rehberi. Published 2016. Accessed on September 13, 2020 at: http://www.romatoloji.org/Dokumanlar/Site/ATKHTR.pdf
• 11 Solovic I, Sester M, Gomez-Reino JJ. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36 (05) 1185-1206
• 12 Cantini F, Nannini C, Niccoli L. et al; SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015; 14 (06) 503-509
• 13 Ai J-W, Zhang S, Ruan Q-L. et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 2015; 42 (12) 2229-2237
• 14 Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013; 57 (09) 1318-1330
• 15 Calzada-Hernández J, Anton-López J, Bou-Torrent R. et al; Carmen García de Vicuña Muñoz de la Nava. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study. Pediatr Rheumatol Online J 2015; 13 (01) 54
• 16 Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?. Rheumatol Int 2012; 32 (09) 2675-2679
• 17 Cagatay T, Aydin M, Sunmez S. et al. Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis. Rheumatol Int 2010; 30 (11) 1459-1463
• 18 Favalli EG, Desiati F, Atzeni F. et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8 (03) 266-273
• 19 Noguera-Julian A, Calzada-Hernández J, Brinkmann F. et al. Tuberculosis disease in children and adolescents on therapy with antitumor necrosis factor-ɑ agents: a collaborative, multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. Clin Infect Dis 2020; 71 (10) 2561-2569
• 20 Turkish Ministry of Health Directorate of Public Health Tuberculosis Incidence by Province. 2018 . Accessed on November 14, 2021 at: https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz_db/dosya/Istatistikler/Yeni/4-Illere_Gore_Olgu_Hzlar_ve_TB_Insidans_2018.pdf
• 21 Demir S, Sadi Aykan F, Öztuna D. [Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune Training and Research Hospital Chest Diseases Clinic for last 8 years (2006-2013)]. Tuberk Toraks 2014; 62 (04) 286-290
• 22 Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors (anti-TNFα). World J Gastroenterol 2018; 24 (25) 2764-2775
• 23 Arbués A, Brees D, Chibout S-D, Fox T, Kammüller M, Portevin D. TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis . PLOS Pathog 2020; 16 (02) e1008312
• 24 Sartori NS, Picon P, Papke A, Neyeloff JL, da Silva Chakr RM. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLoS One 2019; 14 (12) e0224963
• 25 Winthrop KL. Tumor necrosis factor-alpha inhibitors and mycobacterial infections. In: Bond EL. ed. UpToDate.
• 26 Guidelines on the management of latent tuberculosis infection. Accessed on September 9, 2020 at: https://apps.who.int/iris/bitstream/handle/10665/136471/9789241548908_eng.pdf?sequence=1 2015
• 27 Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 2006; 10 (11) 1192-1204
• 28 WHO. World Health Organization Latent tuberculosis infection Updated and consolidated guidelines for programmatic management. 2018 . Accessed on November 10, 2021 at: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf
• 29 Chiappini E, Lo Vecchio A, Garazzino S. et al; Italian Pediatric TB Study Group. Recommendations for the diagnosis of pediatric tuberculosis. Eur J Clin Microbiol Infect Dis 2016; 35 (01) 1-18
• 30 Marino A, Chiappini E, Cimaz R, Simonini G. Prebiologic therapy tuberculosis screening experience in a pediatric rheumatology center: TST and IGRA are both necessary. Pediatr Infect Dis J 2017; 36 (04) 440-441
• 31 Kim EY, Lim JE, Jung JY. et al. Performance of the tuberculin skin test and interferon-γ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009; 9 (01) 207
• 32 Pyo J, Cho S-K, Kim D, Sung Y-K. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases. Korean J Intern Med (Korean Assoc Intern Med) 2018; 33 (06) 1241-1251
• 33 Kang YA, Lee HW, Yoon HI. et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293 (22) 2756-2761
• 34 Zellweger JP, Sotgiu G, Corradi M, Durando P. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med Lav 2020; 111 (03) 170-183
• 35 Abubakar I, Drobniewski F, Southern J. et al; PREDICT Study Team. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis 2018; 18 (10) 1077-1087
• 36 Mitchell CS, Gershon RRM, Lears MK. et al. Risk of tuberculosis in correctional healthcare workers. J Occup Environ Med 2005; 47 (06) 580-586
• 37 Winje BA, White R, Syre H. et al. Stratification by interferon-γ release assay level predicts risk of incident TB. Thorax 2018;(April):thoraxjnl-2017-211147
• 38 Hesseling AC, Mandalakas AM, Kirchner HL. et al. Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. Thorax 2009; 64 (10) 840-846
• 39 Okada K, Mao TE, Mori T. et al. Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 2008; 136 (09) 1179-1187
• 40 Debord C, De Lauzanne A, Gourgouillon N. et al. Interferon-gamma release assay performance for diagnosing tuberculosis disease in 0- to 5-year-old children. Pediatr Infect Dis J 2011; 30 (11) 995-997
• 41 Moyo S, Isaacs F, Gelderbloem S. et al. Tuberculin skin test and QuantiFERON® assay in young children investigated for tuberculosis in South Africa. Int J Tuberc Lung Dis 2011; 15 (09) 1176-1181 , i
• 42 Pavić I, Topić RZ, Raos M, Aberle N, Dodig S. Interferon-γ release assay for the diagnosis of latent tuberculosis in children younger than 5 years of age. Pediatr Infect Dis J 2011; 30 (10) 866-870
• 43 Chiappini E, Bonsignori F, Mazzantini R. et al. Interferon-gamma release assay sensitivity in children younger than 5 years is insufficient to replace the use of tuberculin skin test in western countries. Pediatr Infect Dis J 2014; 33 (12) 1291-1293
• 44 Elliot C, Marais B, Williams P. et al. Tuberculin skin test versus interferon-gamma release assay in refugee children: a retrospective cohort study. J Paediatr Child Health 2018; 54 (08) 834-839
• 45 Debulpaep S, Corbière V, Levy J. et al. Contribution of QuantiFERON-TB Gold-in-Tube to the diagnosis of Mycobacterium tuberculosis infection in young children in a low TB prevalence country. Front Pediatr 2019; 7: 291
• 46 Wendorf KA, Lowenthal P, Feraud J, Cabanting N, Murto C. Interferon-γ release assays for tuberculosis infection diagnosis in refugees <5 years old. Pediatrics 2020; 146 (04) e20200715